Stock listing

KRX:389470 Inventage Lab, Inc. (인벤티지랩) 주가

Follow Inventage Lab, Inc. into a list and get an email when it puts out news.

Share price · KRX:389470

₩18,690 KRW -550 (-2.9%)

Close on Nov 20, 2026

Past year -71.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
₩18,590 – ₩19,490 KRWNov 20, 2026
Volume
27,254 sharesNov 20, 2026
Market cap
₩248.7B KRWAt the close on Nov 20, 2026 · price × 13.31M shares outstanding
52-week range
₩18,100 – ₩101,700 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
₩1.98B KRWMedian day 53,892 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Inventage Lab, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:389470 · KRW, adjusted for splits

DayCloseChange%OpenHighLowVolume
₩18,690-550-2.9%₩18,810₩19,490₩18,59027,254
₩19,240+1,040+5.7%₩18,400₩19,450₩18,31047,339
₩18,200-730-3.9%₩18,400₩18,600₩18,10038,545
₩18,930-1,270-6.3%₩20,400₩20,400₩18,67045,056
₩20,200-450-2.2%₩20,600₩22,000₩20,05050,988
₩20,650-1,000-4.6%₩21,400₩21,800₩20,40073,252
₩21,650+750+3.6%₩20,400₩22,050₩20,40037,879
₩20,900+1,150+5.8%₩20,000₩21,000₩19,97039,533
₩19,750+200+1.0%₩19,650₩20,500₩19,16046,345
₩19,550-1,700-8.0%₩19,580₩20,550₩19,33060,825
₩21,250-750-3.4%₩22,850₩23,700₩21,25053,561
₩22,000+100+0.5%₩22,200₩22,200₩20,40054,351
₩21,900-850-3.7%₩22,600₩22,850₩21,70045,304
₩22,750+650+2.9%₩21,500₩23,900₩21,50047,656
₩22,100-900-3.9%₩22,800₩22,800₩21,80049,176
₩23,000-950-4.0%₩23,750₩23,850₩22,65063,495
₩23,950+1,150+5.0%₩22,950₩25,150₩22,95070,236
₩22,800-50-0.2%₩23,350₩24,450₩22,75044,220
₩22,850-1,500-6.2%₩24,000₩24,050₩22,85043,714
₩24,350-750-3.0%₩24,300₩24,400₩23,30050,913
₩25,100-1,100-4.2%₩25,800₩27,150₩25,00081,872
₩26,200+1,100+4.4%₩25,800₩27,500₩25,55096,845
₩25,100-50-0.2%₩25,450₩25,950₩24,10054,265
₩25,150+400+1.6%₩23,650₩25,300₩23,50041,870
₩24,750+600+2.5%₩24,400₩25,600₩23,850148,545
₩24,150-2,550-9.6%₩24,650₩25,850₩23,65088,942
₩26,700+3,350+14.3%₩23,400₩27,900₩23,150141,390
₩23,350-1,200-4.9%₩25,400₩25,400₩22,550124,245
₩24,550-2,050-7.7%₩26,700₩27,000₩24,25048,248
₩26,600-3,350-11.2%₩29,250₩29,250₩26,600141,934
₩29,950+2,250+8.1%₩27,900₩34,000₩27,600402,634
₩27,700-600-2.1%₩27,550₩28,600₩26,75097,974
₩28,300-900-3.1%₩28,800₩30,400₩28,200106,626
₩29,200+3,400+13.2%₩25,250₩29,450₩25,100204,512
₩25,800+2,050+8.6%₩23,700₩26,450₩23,500149,288
₩23,750-150-0.6%₩25,400₩25,600₩23,600127,336
₩23,900-600-2.4%₩25,000₩25,450₩23,70061,841
₩24,500-500-2.0%₩25,150₩25,300₩24,45045,287
₩25,000-650-2.5%₩25,700₩25,700₩24,95075,412
₩25,650+200+0.8%₩31,050₩31,050₩25,550369,080
₩25,450-600-2.3%₩25,950₩26,600₩24,80090,327
₩26,050+1,550+6.3%₩24,300₩26,100₩24,30068,058
₩24,500-750-3.0%₩25,250₩25,250₩23,80084,400
₩25,250+300+1.2%₩25,000₩26,000₩24,650123,477
₩24,950-350-1.4%₩24,950₩26,100₩24,25059,306
₩25,300-150-0.6%₩24,400₩25,750₩24,40054,222
₩25,450-100-0.4%₩24,900₩25,450₩24,55055,395
₩25,550-200-0.8%₩25,750₩25,900₩25,20041,084
₩25,750-450-1.7%₩26,550₩26,700₩25,75038,938
₩26,200-600-2.2%₩26,750₩27,700₩26,10036,281
₩26,800+850+3.3%₩26,700₩27,150₩25,50045,404
₩25,950-1,550-5.6%₩27,850₩27,850₩25,47546,502
₩27,500-2,000-6.8%₩30,200₩30,300₩27,50068,216
₩29,500+1,150+4.1%₩28,850₩29,700₩28,25031,895
₩28,350-700-2.4%₩28,650₩28,900₩27,55033,582
₩29,050-150-0.5%₩29,650₩29,800₩28,10035,582
₩29,200-750-2.5%₩29,850₩30,350₩28,95045,074
₩29,950+250+0.8%₩30,650₩30,850₩29,00032,508
₩29,700-200-0.7%₩29,500₩29,850₩27,90039,615
₩29,900+1,450+5.1%₩29,000₩30,700₩28,60053,239
₩28,450-1,800-6.0%₩29,200₩29,300₩27,80046,835
₩30,250+150+0.5%₩33,500₩33,550₩29,95083,623
Ticker
KRX:389470
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
KRX
Currency
KRW

Inventage Lab, Inc. on 6ix

Sector
Health care
Industry
Biotechnology

Valuation

EV/sales 61.3× against a median of 37.6×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
₩151.5B KRW
P/E
Loss
EV/sales
61.3×
EV/EBITDA
Negative EBITDA
Price/book
2.8×
Gross margin
−179.0%
Operating margin
Revenue too small
Net margin
−127.0%
Debt to equity
0.2×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Inventage Lab, Inc. · KRX:389470US$185.9MUS$113.3Mn/a61.3×n/a2.8×−127.0%0.2×n/a
SillaJen, Inc. · KRX:215600US$193.5MUS$141.7Mn/a17.6×n/a2.6×−223.8%0.0×n/a
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
Inhibikase Therapeutics, Inc. · NASDAQ:IKTUS$185.2M−US$8.17Mn/an/an/a1.0×n/a0.0×1.50
Antengene Corporation Limited · HKEX:6996US$183.1MUS$107.1Mn/a6.8×n/a1.3×−227.0%0.3×n/a
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Korro Bio, Inc. · NASDAQ:KRROUS$179.4MUS$74.36Mn/a57.6×n/a2.0×n/a0.0×1.46
Median of the othersUS$184.1MUS$110.8M37.6×1.3×−223.8%0.0×1.34

Team and board

OfficerRole
Ju Hee KimChief Executive Officer

Financials

Annual, in KRW

Income statement

LineFY2025FY2024FY2023FY2022
Revenue2.94B1.78B658.2M3.72B
Cost of revenue5.88B28.6M74.4M401.2M
Gross profit-2.94B1.75B583.8M3.32B
Research and development19.5B16.2B12.2B11.0B
Selling, general and administrative2.05B1.34B1.57B1.21B
Operating income-28.4B-19.0B-16.0B-10.9B
Depreciation and amortization7.62B3.83B2.61B2.42B
EBITDA-20.8B-15.1B-13.4B-8.48B
Interest expense4.14B2.14B883.1M103.4M
Income before tax-13.7B-19.2B-27.0B-10.6B
Net income-8.46B-17.0B-27.0B-10.6B
Earnings per share, basic-637.05-1,692.03-3,193.23-1,268.70

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents14.5B17.3B18.5B15.8B
Short-term investments11.3B23.0B3.13B8.04B
Receivables1.52B863.6M167.7M40.9M
Inventory887.6M10.1M45.7M131.4M
Current assets40.0B49.2B26.2B25.3B
Goodwill5.92B
Total assets110.6B72.3B45.2B34.9B
Accounts payable2.47B
Current liabilities19.8B11.0B28.9B2.61B
Long-term debt2.34B7.09B1.66B
Total liabilities29.8B39.7B40.8B4.43B
Shareholders' equity64.5B32.6B4.41B30.4B
Shares outstanding13.3M10.0M8.45M8.35M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-20.3B-13.8B-11.7B-5.19B
Capital spending-7.26B-4.22B-7.14B-1.98B
Free cash flow-27.6B-18.0B-18.9B-7.17B
Share buybacks-3.88M
Change in cash-2.80B-1.22B2.70B-3.48B

Open Financials

Cap table

Built by 6ix from Inventage Lab, Inc.’s releases

Common shares
13,307,708
Fully diluted
13,307,708

Fully diluted

LineShares
Common shares13,307,708

Share count over time

CountShares
Nov 22, 202613,307,708

Open Cap table

Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ju Hee KimChief Executive Officer · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Inventage Lab, Inc.